Table 1 Patient characteristics N = 254
From: Cardiovascular risk management in patients with active Ankylosing Spondylitis: a detailed evaluation
Demographic | |
|---|---|
Age, years (median, IQR) | 42 (35–51) |
Male (number, percentage) | 170 (67%) |
Disease status | |
Disease duration, years (median, IQR) | 7 (2–10) |
HLA-B27 positive (number, percentage) | 196 (77%) |
C-reactive protein, mg/l (median, IQR) | 8 (3–25) |
Erythrocyte sedimentation rate, mm/h (median, IQR) | 19 (7–37) |
BASDAI (0–10) (mean, SD) | 5.9 ± 1.9 |
CV risk factors | |
Prior CVD (number, percentage) | 8 (3%) |
Myocardial infarction (number) | 4 |
TIA/CVA (number) | 4 |
Peripheral arterial disease (number) | 0 |
Smoking (number, percentage) | 109 (43%) |
Systolic blood pressure, mmHg (mean, SD) | 127 ± 17 |
Diastolic blood pressure, mmHg (mean, SD) | 81 ± 10 |
Hypertension (SBP ≥ 140 and/or DBP ≥ 90 and/or antihypertensive drugs) (number, percentage) | 81 (32%) |
Hypercholesterolemia (TC ≥ 6,5 mmol/L and/or cholesterol lowering drugs) (number, percentage) | 30 (12%) |
Diabetes type 2 (number, percentage) | 5 (2%) |
Body mass index, kg/m2 (mean, SD) | 26.2 ± 4.6 |
Overweight (≥25 BMI) (number, percentage) | 134 (53%) |
Kidney function (eGRF Cockcroft Gault) ml/min (mean, SD) | 125.5 ± 34.2 |
Lipid levels | |
Total cholesterol (mmol/l) (mean, SD) | 4.96 ± 0.94 |
Triglycerides (mmol/l) (median, IQR) | 1.28 (0.92-1.87) |
HDL cholesterol (mmol/l) (mean, SD) | 1.32 ± 0.39 |
LDL cholesterol (mmol/l) (mean, SD) | 2.92 ± 0.81 |
Total cholesterol/HDL-C ratio (mean, SD) | 4.05 ± 1.39 |
Medication | |
Statins (number, percentage) | 16 (6%) |
Antihypertensive drugs (number, percentage) | 36 (14%) |
NSAIDs (number, percentage) | 180 (71%) |
Diclofenac (number, percentage) | 46 (26%) |
Etoricoxib (number, percentage) | 41 (23%) |
Naproxen (number, percentage) | 29 (16%) |
Ibuprofen (number, percentage) | 21 (12%) |
Other (number, percentage) | 43 (23%) |